NCT04747236: Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL |
|
|
| Recruiting | 2 | 50 | US | Azacytidine, Vidaza, Romidepsin, Istodax, Belinostat, Beleodaq, Pralatrexate, Folotyn, Gemcitabine, Gemzar | University of Virginia, Celgene | PTCL | 06/26 | 06/28 | | |
NCT03161223: Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma |
|
|
| Recruiting | 1/2 | 148 | US | Durvalumab, MEDI4736, Pralatrexate, Folotyn, Romidepsin, Depsipeptide, 5-Azacitidine, Vidaza, Oral 5-Azacitidine | University of Virginia | Lymphoma, T-Cell | 02/23 | 02/23 | | |
NCT03598998: Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas |
|
|
| Active, not recruiting | 1/2 | 13 | US | Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Pralatrexate, 10-propargyl-10-deazaaminopterin, Folotyn, PDX | City of Hope Medical Center, National Cancer Institute (NCI) | Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Hepatosplenic T-Cell Lymphoma, Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma, Recurrent Mycosis Fungoides, Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Anaplastic Large Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Enteropathy-Associated T-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Hepatosplenic T-Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Subcutaneous Panniculitis-Like T-Cell Lymphoma | 05/23 | 12/24 | | |
